Golidocitinib Pilot Study in Mycosis Fungoides and T-LGLL Initiated
A pilot study of golidocitinib is enrolling patients with advanced-stage mycosis fungoides/Sézary syndrome and T-cell large granular lymphocytic leukemia.
Company
Pharmaceutical intelligence for Dizal Pharmaceuticals with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.